Abstract
As of 1st of September 2020, the COVID-19 pandemic has reached an unprecedented level of more than 25 million cases with more than 850,000 deaths. Moreover, all the drug candidates are still undergoing testing in clinical trials. In this regard, a breakthrough in drug design is necessary. One strategy to devise lead compounds is leveraging natural products as a lead source. Several companies and research institutes are currently developing anti-SARS-CoV-2 lead from natural products. Flavonoids are well known as a class of antiviral compounds library. The objective of this research is to employ virtual screening methods for obtaining the best lead compounds from the library of flavonoid compounds. This research employed virtual screening methods that comprised of downloading the protein and lead compound structures, QSAR analysis prediction, iterations of molecular docking simulation, and ADME-TOX simulation for toxicity prediction. The QSAR analysis found that the tested compounds have broad-spectrum antiviral activity, and some of them exhibit specific binding to the 3C-like Protease of the Coronavirus. Moreover, juglanin was found as the compound with the fittest binding with the Protease enzyme of SARS-CoV-2. Although most of the tested compounds are deemed toxic by the ADME-Tox test, further research should be conducted to comprehend the most feasible strategy to deliver the drug to the infected lung cells. The juglanin compound is selected as the fittest candidate as the SARS-CoV-2 lead compound in the tested flavonoid samples. However, further research should be conducted to observe the lead delivery method to the cell.
Keywords: SARS-COV-2, SARS-COV-2 3CLpro, flavonoid, molecular docking, QSAR, ADME-Tox, COVID-19.
Graphical Abstract
Coronaviruses
Title:Virtual Screening of the Flavonoids Compounds with the SARS-CoV-2 3C-like Protease as the Lead Compounds for the COVID-19
Volume: 2 Issue: 11
Author(s): Gabriella Patricia Adisurja and Arli Aditya Parikesit*
Affiliation:
- Department of Bioinformatics, School of Life Sciences, Indonesia International Institute of Life Sciences (i3L), Jakarta,Indonesia
Keywords: SARS-COV-2, SARS-COV-2 3CLpro, flavonoid, molecular docking, QSAR, ADME-Tox, COVID-19.
Abstract: As of 1st of September 2020, the COVID-19 pandemic has reached an unprecedented level of more than 25 million cases with more than 850,000 deaths. Moreover, all the drug candidates are still undergoing testing in clinical trials. In this regard, a breakthrough in drug design is necessary. One strategy to devise lead compounds is leveraging natural products as a lead source. Several companies and research institutes are currently developing anti-SARS-CoV-2 lead from natural products. Flavonoids are well known as a class of antiviral compounds library. The objective of this research is to employ virtual screening methods for obtaining the best lead compounds from the library of flavonoid compounds. This research employed virtual screening methods that comprised of downloading the protein and lead compound structures, QSAR analysis prediction, iterations of molecular docking simulation, and ADME-TOX simulation for toxicity prediction. The QSAR analysis found that the tested compounds have broad-spectrum antiviral activity, and some of them exhibit specific binding to the 3C-like Protease of the Coronavirus. Moreover, juglanin was found as the compound with the fittest binding with the Protease enzyme of SARS-CoV-2. Although most of the tested compounds are deemed toxic by the ADME-Tox test, further research should be conducted to comprehend the most feasible strategy to deliver the drug to the infected lung cells. The juglanin compound is selected as the fittest candidate as the SARS-CoV-2 lead compound in the tested flavonoid samples. However, further research should be conducted to observe the lead delivery method to the cell.
Export Options
About this article
Cite this article as:
Adisurja Patricia Gabriella and Parikesit Aditya Arli *, Virtual Screening of the Flavonoids Compounds with the SARS-CoV-2 3C-like Protease as the Lead Compounds for the COVID-19, Coronaviruses 2021; 2 (11) : e130921191637 . https://dx.doi.org/10.2174/2666796702666210222105547
DOI https://dx.doi.org/10.2174/2666796702666210222105547 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neutralization of SARS-CoV-2 Spike Protein via Natural Compounds: A Multilayered High Throughput Virtual Screening Approach
Current Pharmaceutical Design Withdrawal Notice: COVID-19: Outbreak to Global
Anti-Infective Agents Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and its Implication for Drug Design
Medicinal Chemistry COVID-19, SARS -CoV-2, Origin, Transmission and Treatment Aspects, A Brief Review
Infectious Disorders - Drug Targets Role of Pulmonary Ultrasound in COVID-19 Pandemics
Current Respiratory Medicine Reviews Coronavirus Pandemic: Role of Bats And Zoonotic Transmission in Humans
Coronaviruses Pathogenesis of COVID-19, Disease Outbreak: A Review
Current Pharmaceutical Biotechnology A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019
Coronaviruses Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation
Current Stem Cell Research & Therapy Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?
Combinatorial Chemistry & High Throughput Screening False Positives in the Early Stages of Drug Discovery
Current Medicinal Chemistry How Does the Covıd-19 Pandemıc Affect the Target 90-90-90?
Current HIV Research Does Metformin Satisfy as an Option for Host-Directed Therapy in COVID-19?
Anti-Infective Agents In Vivo and In Vitro Evaluation of the Therapeutic Potential of Some Turkish Scorzonera Species as Wound Healing Agent
Current Pharmaceutical Design Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review
Current Respiratory Medicine Reviews Novel Coronavirus 2019 Outbreak: A Global Epidemic
Letters in Drug Design & Discovery Natural Products as Anti-COVID-19 Agents: An <i>In Silico</i> Study
Coronaviruses Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence
Current Pharmaceutical Design COVID-19 Effect: Time to Change the Way of Research
Coronaviruses Asymmetric Organocatalyzed Warfarin Synthesis in Aqueous and Nonaqueous Media: A Discussion in the Era of COVID-19 Pandemic
Current Organocatalysis